Sandoz
FDA approves generic Copaxone for multiple sclerosis
April 17, 2015Sales and Marketing FDA, Sandoz, Teva, glatiramer acetate injection, glatopa
The FDA has signed-off on the first generic version of Copaxone to treat people with relapsing forms of multiple sclerosis …
Novartis secures first US biosimilar product
March 6, 2015Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz
Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …
Sandoz earns historic first FDA biosimilar vote
January 8, 2015Sales and Marketing FDA, Humira, Novartis, Sandoz, Zarxio, filgrastim, zarzio
Sandoz has taken a huge step forward in the race to be the first company to market a biosimilar in …
Novartis biosimilar rivals Amgen offering
December 9, 2014Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, filgrastim, zarzio
An investigational biosimilar by Novartis’ generic pharma arm Sandoz has been found to have comparable safety and efficacy readings to …
€16 million fines for J&J and Novartis
December 12, 2013Medical Communications, Sales and Marketing EU, J&J, JJ, Novartis, Sandoz, fentanyl, fines
The European Commission has slapped multi-million euro fines on Johnson & Johnson and Novartis for what it says were ‘shocking’ …
Packaging errors spark fourth oral contraceptive recall
June 12, 2012Manufacturing and Production Introvale, Novartis, Sandoz, manufacturing, recall
There has been yet another case of an oral contraceptive being recalled because packaging errors could lead to unwanted pregnancy, …
Novartis Q1 earnings slide down
April 26, 2012Sales and Marketing Novartis, Q1, Sandoz, generics, gilenya
Generic competition and problems at a US plant were among the reasons why Novartis’ sales and profit dipped in the …
High Court rules against Seroquel XR patent
March 23, 2012Sales and Marketing Accord, AstraZeneca, Sandoz, Seroquel, Teva
A British High Court has ruled that AstraZeneca’s patent on its new formulation of the antipsychotic Seroquel is invalid. Seroquel …
Sandoz falls foul of ABPI Code
March 7, 2012Medical Communications, Sales and Marketing ABPI Code of Practice, Sandoz
Sandoz has been rapped over the knuckles for offering non-approved bags and bottles to patients.It was found to be offering …
Shortages likely as Sandoz’s Canadian plant woes continue
February 20, 2012Manufacturing and Production FDA, Novartis, Sandoz
Ongoing compliance problems at a plant in Canada operated by Novartis’ generics subsidiary Sandoz look set to cause supply disruptions …
Novartis warned over standards at generics sites
December 9, 2011Manufacturing and Production CGMP Failures, FDA compliance, Novartis, Sandoz
The FDA has warned Novartis that three North American production facilities operated by its generics subsidiary Sandoz are failing to …
Pharma manufacturing news in brief
January 21, 2011Manufacturing and Production Cambrex, Faron Pharmaceuticals, McNeil Consumer Healthcare, NextPharma Technologies, Rentschler Biotechnologie, Sandoz, ShangPharma, Sun European Partners, Teva Pharmaceuticals USA, Unilife Corp
Another J&J recall in the US, plus a round-up of product recalls, acquisitions, facility updates and new contracts in the …
More US recalls as bill seeks greater FDA powers
January 10, 2011Manufacturing and Production Centocor Ortho Biotech, Cumberland Pharmaceuticals, FDA, RiteDose Corp, Sandoz, Sigma-tau Pharmasource, Teva Pharmaceuticals, manufacturing compliance, recalls
Product recalls continue to make headlines in the pharmaceutical sector, with several new incidents either side of the New Year …
Generic Lovenox to dent Sanofi’s earnings
July 26, 2010Sales and Marketing Lovenox, Sandoz, Sanofi-Aventis, generics
A generic version of Sanofi-Aventis’ blockbuster anti-blood clot treatment Lovenox has just gained approval in the US, signaling a rapid …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
